Clinical core of the Alzheimer's disease neuroimaging initiative: Progress and plans

Paul S. Aisen, Ronald C. Petersen, Michael C. Donohue, Anthony Gamst, Rema Raman, Ronald G. Thomas, Sarah Walter, John Q. Trojanowski, Leslie M. Shaw, Laurel A Beckett, Clifford R. Jack, William Jagust, Arthur W. Toga, Andrew J. Saykin, John C. Morris, Robert C. Green, Michael W. Weiner

Research output: Contribution to journalArticle

222 Citations (Scopus)

Abstract

The Clinical Core of the Alzheimer's Disease Neuroimaging Initiative (ADNI) has provided clinical, operational, and data management support to ADNI since its inception. This article reviews the activities and accomplishments of the core in support of ADNI aims. These include the enrollment and follow-up of more than 800 subjects in the three original cohorts: healthy controls, amnestic mild cognitive impairment (now referred to as late MCI, or LMCI), and mild Alzheimer's disease (AD) in the first phase of ADNI (ADNI 1), with baseline longitudinal, clinical, and cognitive assessments. These data, when combined with genetic, neuroimaging, and cerebrospinal fluid measures, have provided important insights into the neurobiology of the AD spectrum. Furthermore, these data have facilitated the development of novel clinical trial designs. ADNI has recently been extended with funding from an NIH Grand Opportunities (GO) award, and the new ADNI GO phase has been launched; this includes the enrollment of a new cohort, called early MCI, with milder episodic memory impairment than the LMCI group. An application for a further 5 years of ADNI funding (ADNI 2) was recently submitted. This funding would support ongoing follow-up of the original ADNI 1 and ADNI GO cohorts, as well as additional recruitment into all categories. The resulting data would provide valuable data on the earliest stages of AD, and support the development of interventions in these critically important populations.

Original languageEnglish (US)
Pages (from-to)239-246
Number of pages8
JournalAlzheimer's and Dementia
Volume6
Issue number3
DOIs
StatePublished - May 2010

Fingerprint

Neuroimaging
Alzheimer Disease
Episodic Memory
Neurobiology
Cerebrospinal Fluid
Clinical Trials

Keywords

  • ADNI
  • Alzheimer's disease
  • Clinical trials

ASJC Scopus subject areas

  • Health Policy
  • Epidemiology
  • Geriatrics and Gerontology
  • Psychiatry and Mental health
  • Cellular and Molecular Neuroscience
  • Developmental Neuroscience
  • Clinical Neurology
  • Medicine(all)

Cite this

Aisen, P. S., Petersen, R. C., Donohue, M. C., Gamst, A., Raman, R., Thomas, R. G., ... Weiner, M. W. (2010). Clinical core of the Alzheimer's disease neuroimaging initiative: Progress and plans. Alzheimer's and Dementia, 6(3), 239-246. https://doi.org/10.1016/j.jalz.2010.03.006

Clinical core of the Alzheimer's disease neuroimaging initiative : Progress and plans. / Aisen, Paul S.; Petersen, Ronald C.; Donohue, Michael C.; Gamst, Anthony; Raman, Rema; Thomas, Ronald G.; Walter, Sarah; Trojanowski, John Q.; Shaw, Leslie M.; Beckett, Laurel A; Jack, Clifford R.; Jagust, William; Toga, Arthur W.; Saykin, Andrew J.; Morris, John C.; Green, Robert C.; Weiner, Michael W.

In: Alzheimer's and Dementia, Vol. 6, No. 3, 05.2010, p. 239-246.

Research output: Contribution to journalArticle

Aisen, PS, Petersen, RC, Donohue, MC, Gamst, A, Raman, R, Thomas, RG, Walter, S, Trojanowski, JQ, Shaw, LM, Beckett, LA, Jack, CR, Jagust, W, Toga, AW, Saykin, AJ, Morris, JC, Green, RC & Weiner, MW 2010, 'Clinical core of the Alzheimer's disease neuroimaging initiative: Progress and plans', Alzheimer's and Dementia, vol. 6, no. 3, pp. 239-246. https://doi.org/10.1016/j.jalz.2010.03.006
Aisen, Paul S. ; Petersen, Ronald C. ; Donohue, Michael C. ; Gamst, Anthony ; Raman, Rema ; Thomas, Ronald G. ; Walter, Sarah ; Trojanowski, John Q. ; Shaw, Leslie M. ; Beckett, Laurel A ; Jack, Clifford R. ; Jagust, William ; Toga, Arthur W. ; Saykin, Andrew J. ; Morris, John C. ; Green, Robert C. ; Weiner, Michael W. / Clinical core of the Alzheimer's disease neuroimaging initiative : Progress and plans. In: Alzheimer's and Dementia. 2010 ; Vol. 6, No. 3. pp. 239-246.
@article{03b1bd3f1c714326945aaf9c826ea222,
title = "Clinical core of the Alzheimer's disease neuroimaging initiative: Progress and plans",
abstract = "The Clinical Core of the Alzheimer's Disease Neuroimaging Initiative (ADNI) has provided clinical, operational, and data management support to ADNI since its inception. This article reviews the activities and accomplishments of the core in support of ADNI aims. These include the enrollment and follow-up of more than 800 subjects in the three original cohorts: healthy controls, amnestic mild cognitive impairment (now referred to as late MCI, or LMCI), and mild Alzheimer's disease (AD) in the first phase of ADNI (ADNI 1), with baseline longitudinal, clinical, and cognitive assessments. These data, when combined with genetic, neuroimaging, and cerebrospinal fluid measures, have provided important insights into the neurobiology of the AD spectrum. Furthermore, these data have facilitated the development of novel clinical trial designs. ADNI has recently been extended with funding from an NIH Grand Opportunities (GO) award, and the new ADNI GO phase has been launched; this includes the enrollment of a new cohort, called early MCI, with milder episodic memory impairment than the LMCI group. An application for a further 5 years of ADNI funding (ADNI 2) was recently submitted. This funding would support ongoing follow-up of the original ADNI 1 and ADNI GO cohorts, as well as additional recruitment into all categories. The resulting data would provide valuable data on the earliest stages of AD, and support the development of interventions in these critically important populations.",
keywords = "ADNI, Alzheimer's disease, Clinical trials",
author = "Aisen, {Paul S.} and Petersen, {Ronald C.} and Donohue, {Michael C.} and Anthony Gamst and Rema Raman and Thomas, {Ronald G.} and Sarah Walter and Trojanowski, {John Q.} and Shaw, {Leslie M.} and Beckett, {Laurel A} and Jack, {Clifford R.} and William Jagust and Toga, {Arthur W.} and Saykin, {Andrew J.} and Morris, {John C.} and Green, {Robert C.} and Weiner, {Michael W.}",
year = "2010",
month = "5",
doi = "10.1016/j.jalz.2010.03.006",
language = "English (US)",
volume = "6",
pages = "239--246",
journal = "Alzheimer's and Dementia",
issn = "1552-5260",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Clinical core of the Alzheimer's disease neuroimaging initiative

T2 - Progress and plans

AU - Aisen, Paul S.

AU - Petersen, Ronald C.

AU - Donohue, Michael C.

AU - Gamst, Anthony

AU - Raman, Rema

AU - Thomas, Ronald G.

AU - Walter, Sarah

AU - Trojanowski, John Q.

AU - Shaw, Leslie M.

AU - Beckett, Laurel A

AU - Jack, Clifford R.

AU - Jagust, William

AU - Toga, Arthur W.

AU - Saykin, Andrew J.

AU - Morris, John C.

AU - Green, Robert C.

AU - Weiner, Michael W.

PY - 2010/5

Y1 - 2010/5

N2 - The Clinical Core of the Alzheimer's Disease Neuroimaging Initiative (ADNI) has provided clinical, operational, and data management support to ADNI since its inception. This article reviews the activities and accomplishments of the core in support of ADNI aims. These include the enrollment and follow-up of more than 800 subjects in the three original cohorts: healthy controls, amnestic mild cognitive impairment (now referred to as late MCI, or LMCI), and mild Alzheimer's disease (AD) in the first phase of ADNI (ADNI 1), with baseline longitudinal, clinical, and cognitive assessments. These data, when combined with genetic, neuroimaging, and cerebrospinal fluid measures, have provided important insights into the neurobiology of the AD spectrum. Furthermore, these data have facilitated the development of novel clinical trial designs. ADNI has recently been extended with funding from an NIH Grand Opportunities (GO) award, and the new ADNI GO phase has been launched; this includes the enrollment of a new cohort, called early MCI, with milder episodic memory impairment than the LMCI group. An application for a further 5 years of ADNI funding (ADNI 2) was recently submitted. This funding would support ongoing follow-up of the original ADNI 1 and ADNI GO cohorts, as well as additional recruitment into all categories. The resulting data would provide valuable data on the earliest stages of AD, and support the development of interventions in these critically important populations.

AB - The Clinical Core of the Alzheimer's Disease Neuroimaging Initiative (ADNI) has provided clinical, operational, and data management support to ADNI since its inception. This article reviews the activities and accomplishments of the core in support of ADNI aims. These include the enrollment and follow-up of more than 800 subjects in the three original cohorts: healthy controls, amnestic mild cognitive impairment (now referred to as late MCI, or LMCI), and mild Alzheimer's disease (AD) in the first phase of ADNI (ADNI 1), with baseline longitudinal, clinical, and cognitive assessments. These data, when combined with genetic, neuroimaging, and cerebrospinal fluid measures, have provided important insights into the neurobiology of the AD spectrum. Furthermore, these data have facilitated the development of novel clinical trial designs. ADNI has recently been extended with funding from an NIH Grand Opportunities (GO) award, and the new ADNI GO phase has been launched; this includes the enrollment of a new cohort, called early MCI, with milder episodic memory impairment than the LMCI group. An application for a further 5 years of ADNI funding (ADNI 2) was recently submitted. This funding would support ongoing follow-up of the original ADNI 1 and ADNI GO cohorts, as well as additional recruitment into all categories. The resulting data would provide valuable data on the earliest stages of AD, and support the development of interventions in these critically important populations.

KW - ADNI

KW - Alzheimer's disease

KW - Clinical trials

UR - http://www.scopus.com/inward/record.url?scp=77955480521&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955480521&partnerID=8YFLogxK

U2 - 10.1016/j.jalz.2010.03.006

DO - 10.1016/j.jalz.2010.03.006

M3 - Article

C2 - 20451872

AN - SCOPUS:77955480521

VL - 6

SP - 239

EP - 246

JO - Alzheimer's and Dementia

JF - Alzheimer's and Dementia

SN - 1552-5260

IS - 3

ER -